Mitochondrial Disorders Treatment Market predicts rise in demand by 2022

Mitochondrial disorders are inherited chronic disorders characterized by a wide range of biochemical and genetic mitochondrial defects and mutations. The disorder affects multiple organs, which includes brain, heart, liver, skeletal muscles, kidney, and respiratory systems. The patients with mitochondrial disorders often suffer from muscle weakness, exercise intolerance, and fatigue due to reduction in mitochondrial respiration, which is caused due to mitochondrial DNA mutations leading to reduced ability to produce cellular adenosine triphosphate (ATP). Despite major advances in understanding of the molecular mechanisms, currently there are no effective treatments for the disease. The treatment of mitochondrial disorders is mostly performed with different vitamins, co-factors, off-label drugs approved for other indications, and nutritional supplements. However, the research organizations and pharmaceutical companies are involved in development of novel drugs with technology advancements including the use of biomarkers, replacement therapies and sophisticated trial designs, thus creating a lucrative opportunity for the market growth.

Get The Holistic SAMPLE With Research Methodology: https://www.coherentmarketinsights.com/insight/request-sample/1650

Mitochondrial Disorders Treatment Market: Market Dynamics

Increasing prevalence of mitochondrial disorders causing significant morbidity and mortality combined with the higher potential of genetic transmission to the next generation are the factors driving the market growth. According to the Wellcome Center for Mitochondrial Research, 2015, about 10 people per 100,000 have a mitochondrial disorders, which often express first in early childhood. According to the Genetic and Rare Disease Information Center, women with mitochondrial genetic disorders have 50% chance with each pregnancy of passing along the altered gene to the offspring, thus indicating the rising burden of the disease. Also, the mitochondrial disorders treatment market is expected to gain significant traction in the future, as the pharmaceutical drugs approved for the treatment of primary mitochondrial disease have orphan drug status, thereby having a greater potential for market approval than conventional pharmaceuticals. Moreover, the approval of novel drug molecules from the regulatory agencies is expected to create a lucrative opportunity for the growth of mitochondrial disorders treatment market. For instance, in April 2018, NeuroVive Pharmaceutical AB received orphan drug designation to KL1333 by the US Food and Drug administration (FDA) for the treatment of inherited mitochondrial respiratory chain diseases (MRCD).

Click To Continue Reading On Mitochondrial Disorders Treatment Market

You may be interested

Business

Tricks Used by Insurance Companies to Deny Legit Claims

media - December 10, 2018

Health insurance companies strategize in making more and more money by paying out as little as possible. Many times, they deny legitimate claims which are covered under…

New Study Suggests Typical Use of Sunscreens Offers Less Sun Protection
Business
Business

New Study Suggests Typical Use of Sunscreens Offers Less Sun Protection

Mohit Joshi - December 10, 2018

Researchers from King's College London revealed that use of sunscreen offers less than half the sun protection as users apply more thinly than manufacturers recommend. In a…

Tamoxifen Market: Segmented by Application and Geography Trends, Growth and Forecasts 2026
Healthcare
Healthcare

Tamoxifen Market: Segmented by Application and Geography Trends, Growth and Forecasts 2026

Albert R - December 10, 2018

Tamoxifen Market report is a research database spread across various pages with multiple tables and figures in it. The research covers a valuable source of perceptive information…

Most from this category